In our experiments, we used GlobotriaosylCERAMIDE (Gb3) and not - as wrongly stated - GlobotriaosylSPHINGOSINE (lyso-Gb3). Nevertheless, the abbreviation we used, "Gb3", is the correct one and accurate throughout the manuscript. The instances in the text where the substance's name is mentioned in full should be corrected; more precisely the title, the abstract (background section) and the Introduction section (3rd line). In those three cases, Globotriaosylsphingosine should be replaced by Globotriaosylceramide. The correct citation is: Namdar M, Gebhard C, Studiger R, Shi Y, Mocharla P, et al. (2012) Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease. PLoS ONE 7(4): e36373. doi:10.1371/journal.pone.0036373